<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="149536">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01735188</url>
  </required_header>
  <id_info>
    <org_study_id>ALX-MCD-502</org_study_id>
    <secondary_id>ALX-MCD-502</secondary_id>
    <nct_id>NCT01735188</nct_id>
  </id_info>
  <brief_title>A Natural History Study of Molybdenum Cofactor and Isolated Sulfite Oxidase Deficiencies</brief_title>
  <official_title>A NATURAL HISTORY STUDY OF MOLYBDENUM COFACTOR AND ISOLATED SULFITE OXIDASE DEFICIENCIES</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexion Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alexion Pharmaceuticals</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United Kingdom: National Health Service (West of Scotland Research Ethics Service)</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary objective:

      Characterize the natural history of MoCD type A in terms of survival

      Secondary objectives:

        1. Evaluate blood and urine for biochemical markers

        2. Evaluate head circumference, seizure activity and neurologic outcomes

        3. To evaluate brain MRI

        4. Compare blood and urine analysis, head circumference, seizure activity and neurologic
           outcomes to MRI findings
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>N/A</study_design>
  <primary_outcome>
    <measure>To characterize the natural history of molybdenum cofactor deficiency (MoCD) type A, the most common subtype of MoCD, in terms of survival</measure>
    <time_frame>September 2014</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate levels of the biochemical markers S-sulfocysteine (SSC), uric acid, and xanthine in blood, urine, and cerebral spinal fluid over time in patients with MoCD and isolated sulfite oxidase (SOX) deficiency.</measure>
    <time_frame>September 2014</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Molybdenum Cofactor and Isolated Sulfite Oxidase Deficiencies</condition>
  <arm_group>
    <arm_group_label>No treatment</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No treatment</intervention_name>
    <arm_group_label>No treatment</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The actual sample size will depend on successful identification of patients with MoCD or
        isolated SOX deficiency
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Both living and deceased patients of any age will be considered for study inclusion.

          2. Diagnosis of MoCD or isolated SOX deficiency

          3. Documented informed consent

        Exclusion Criteria:

        1. MoCD Type A patient who was in Study ALX-MCD-501
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alexion Pharmaceuticals (Sponsor)</last_name>
    <email>clinicaltrials@alxn.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Woodinville</city>
        <state>Washington</state>
        <zip>98072</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexion Pharmaceuticals (Sponsor)</last_name>
      <email>clinicaltrials@alxn.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexion Pharmaceuticals (Sponsor)</last_name>
      <email>clinicaltrials@alxn.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Badalona</city>
        <state>Catalonia</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexion Pharmaceuticals (Sponsor)</last_name>
      <email>clinicaltrials@alxn.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Esplugues de Llobregat</city>
        <zip>08950</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexion Pharmaceuticals (Sponsor)</last_name>
      <email>clinicaltrials@alxn.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexion Pharmaceuticals (Sponsor)</last_name>
      <email>clinicaltrials@alxn.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexion Pharmaceuticals (Sponsor)</last_name>
      <email>clinicaltrials@alxn.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexion Pharmaceuticals (Sponsor)</last_name>
      <email>clinicaltrials@alxn.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Kayseri</city>
        <zip>38010</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexion Pharmaceuticals (Sponsor)</last_name>
      <email>clinicaltrials@alxn.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Israel</country>
    <country>Spain</country>
    <country>Turkey</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 3, 2013</lastchanged_date>
  <firstreceived_date>November 26, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Natural history study</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Amino Acid Metabolism, Inborn Errors</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Molybdenum</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
